2024. Deucravacitinib in Plaque Psoriasis: 4-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. SKIN The Journal of Cutaneous Medicine. 8, 6 (Nov. 2024), s423. DOI:https://doi.org/10.25251/skin.8.supp.423.